Series A · 2026-11-12 · Healthcare
Orakl Oncology raises $32.4M
65
AI Score
Amount
$32.4M
Round
Series A
Lead
Norrsken VC, Singular
HQ
FR
Why it matters: The round shows investors backing a platform that pairs patient-derived tumor organoids with AI to forecast trial outcomes, a concrete bet on cutting late-stage oncology failure.
Orakl Oncology, a French TechBio spun out of the Gustave Roussy Institute, raised a €30M ($34M) Series A co-led by Norrsken VC and Singular.
- Participants:
- InfraVia Capital Partners, Serena, Patient Autonome Fund, Bpifrance, Teampact Ventures, Plug and Play, Verve Ventures VC, Speedinvest, HCVC, Dorothy Chou, Thomas Wolf, Stanislas Polu
- Source:
- EU-Startups Funding ↗ · Midu summary
Other rounds by Orakl Oncology
Deal Dossier PRO
Pro feature
Deal Dossier for Orakl Oncology
Company, lead and participating investors, founders, and verified public contact channels — sourced, generated on demand.
Generate dossier — ProFigures marked company-reported are unaudited. Not investment advice. Request a correction or removal (team@midu.si).
Recent Healthcare rounds
Subscribe to the newsletters
Free, by email. No account needed. Pick one or both.
No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.
Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing